Russell James Hubbard Ryan

Russell James Hubbard Ryan

Auto-generated profile, based on publicly available information

Russell James Hubbard Ryan

Department of Pathology, University of Michigan, Ann Arbor, Michigan, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2014 in Nature
Verified
Journal Article
Open access
PDF file
KFKyle Kai-How Farh
Kyle Kai-How Farh
AMAlex Marson
Alex Marson
JZJiang Zhu
Jiang Zhu
MKMarkus KLEINEWIETFELD
Markus KLEINEWIETFELD
WHWilliam J. Housley
William J. Housley
BBBradley E. Bernstein
Bradley E. Bernstein
Genome-wide association studies have identified loci underlying human diseases, but the causal nucleotide changes and mechanisms remain largely unknown. Here we developed a fine-mapping algorithm to identify candidate causal variants for 21 autoimmune diseases from genotyping data. We integrated these predictions with transcription and cis-regulatory element annotations, derived by mapping RNA and chromatin in primary immune cells, including resting and stimulated CD4+ T-cell subsets, regulatory T cells, CD8+ T cells, B cells, and monocytes. We find that ∼90% of causal variants are non-coding, with ∼60% mapping to immune-cell enhancers, many of which gain histone acetylation and transcribe enhancer-associated RNA upon immune stimulation. Causal variants tend to occur near binding sites for master regulators of immune differentiation and stimulus-dependent gene activation, but only 10–20% directly alter recognizable transcription factor binding motifs. Rather, most non-coding risk variants, including those that alter gene expression, affect non-canonical sequence determinants not well-explained by current gene regulatory models.

30 January 2012 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
VCVirna Cortez-Retamozo
Virna Cortez-Retamozo
MEMartin Etzrodt
Martin Etzrodt
ANAndita Newton
Andita Newton
PRPhilipp J. Rauch
Philipp J. Rauch
ACAleksey Chudnovskiy
Aleksey Chudnovskiy
MPMikael J. Pittet
Mikael J. Pittet
Tumor-associated macrophages (TAMs) and tumor-associated neutrophils (TANs) can control cancer growth and exist in almost all solid neoplasms. The cells are known to descend from immature monocytic and granulocytic cells, respectively, which are produced in the bone marrow. However, the spleen is also a recently identified reservoir of monocytes, which can play a significant role in the inflammatory response that follows acute injury. Here, we evaluated the role of the splenic reservoir in a genetic mouse model of lung adenocarcinoma driven by activation of oncogenic Kras and inactivation of p53. We found that high numbers of TAM and TAN precursors physically relocated from the spleen to the tumor stroma, and that recruitment of tumor-promoting spleen-derived TAMs required signaling of the chemokine receptor CCR2. Also, removal of the spleen, either before or after tumor initiation, reduced TAM and TAN responses significantly and delayed tumor growth. The mechanism by which the spleen was able to maintain its reservoir capacity throughout tumor progression involved, in part, local accumulation in the splenic red pulp of typically rare extramedullary hematopoietic stem and progenitor cells, notably granulocyte and macrophage progenitors, which produced CD11b + Ly-6C hi monocytic and CD11b + Ly-6G hi granulocytic cells locally. Splenic granulocyte and macrophage progenitors and their descendants were likewise identified in clinical specimens. The present study sheds light on the origins of TAMs and TANs, and positions the spleen as an important extramedullary site, which can continuously supply growing tumors with these cells.

1 July 2017 in Cell
Verified
Journal Article
Closed access
RGRajat M. Gupta
Rajat M. Gupta
JHJoseph Hadaya
Joseph Hadaya
ATAditi Trehan
Aditi Trehan
SZSeyedeh M. Zekavat
Seyedeh M. Zekavat
CRCarolina Roselli
Carolina Roselli
SKSekar Kathiresan
Sekar Kathiresan

1 February 2016 in Nature Genetics
Verified
Journal Article
Open access
PDF file
Yotam DrierYotam Drier
Yotam Drier
MCMatthew J Cotton
Matthew J Cotton
KWKaylyn E Williamson
Kaylyn E Williamson
SGShawn M Gillespie
Shawn M Gillespie
RRRussell J H Ryan
Russell J H Ryan
BBBradley E Bernstein
Bradley E Bernstein
Bradley Bernstein, Birgit Knoechel and colleagues identify super-enhancer translocations that drive overexpression of MYB in adenoid cystic carcinoma (ACC). They find that MYB binds to the translocated enhancers and to other active enhancers that drive different regulatory programs in alternate cell lineages in ACC. Translocation events are frequent in cancer and may create chimeric fusions or 'regulatory rearrangements' that drive oncogene overexpression. Here we identify super-enhancer translocations that drive overexpression of the oncogenic transcription factor MYB as a recurrent theme in adenoid cystic carcinoma (ACC). Whole-genome sequencing data and chromatin maps highlight distinct chromosomal rearrangements that juxtapose super-enhancers to the MYB locus. Chromosome conformation capture confirms that the translocated enhancers interact with the MYB promoter. Remarkably, MYB protein binds to the translocated enhancers, creating a positive feedback loop that sustains its expression. MYB also binds enhancers that drive different regulatory programs in alternate cell lineages in ACC, cooperating with TP63 in myoepithelial cells and a Notch program in luminal epithelial cells. Bromodomain inhibitors slow tumor growth in ACC primagraft models in vivo. Thus, our study identifies super-enhancer translocations that drive MYB expression and provides insight into downstream MYB functions in alternate ACC lineages.

1 February 2013 in Immunity
Verified
Journal Article
Closed access
VCVirna Cortez-Retamozo
Virna Cortez-Retamozo
MEMartin Etzrodt
Martin Etzrodt
ANAndita Newton
Andita Newton
RRRussell Ryan
Russell Ryan
FPFerdinando Pucci
Ferdinando Pucci
MPMikael J. Pittet
Mikael J. Pittet

1 January 2016 in Molecular Cell
Verified
Journal Article
Closed access
PGPeter van Galen
Peter van Galen
AVAaron D. Viny
Aaron D. Viny
OROren Ram
Oren Ram
RRRussell J.H. Ryan
Russell J.H. Ryan
MCMatthew J. Cotton
Matthew J. Cotton
BBBradley E. Bernstein
Bradley E. Bernstein